• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

    6/28/21 5:08:40 AM ET
    $NEOS
    Major Pharmaceuticals
    Health Care
    Get the next $NEOS alert in real time by email
    New Drug Application (NDA): 205489
    Company: NEOS THERAPS INC
    • Email
    • Medication Guide

    Products on NDA 205489

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    COTEMPLA XR-ODT METHYLPHENIDATE 8.6MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription None Yes No
    COTEMPLA XR-ODT METHYLPHENIDATE 17.3MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription None Yes No
    COTEMPLA XR-ODT METHYLPHENIDATE 25.9MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 205489

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    06/19/2017 ORIG-1 Approval Type 3 - New Dosage Form STANDARD Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/205489Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205489Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    06/25/2021 SUPPL-7 Labeling-Package Insert

    Label is not available on this site.

    Labels for NDA 205489

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    06/19/2017 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf
    Get the next $NEOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

      – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 12, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system

      3/12/21 9:04:16 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

      – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 10, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system

      3/10/21 4:01:00 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results

      PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2020. “Despite the unique challenges of 2020, Hercules was able to reach several new financial and operating milestones,” stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. “Notably, we closed over $1.0 billion in new debt and equity commitments

      2/23/21 4:10:00 PM ET
      $ACEV
      $AYTU
      $ASPL
      $PACE
      Semiconductors
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

      2/16/21 8:52:52 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

      2/12/21 5:07:54 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

      2/12/21 6:47:18 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care

    $NEOS
    SEC Filings

    See more
    • SEC Form EFFECT filed by Neos Therapeutics, Inc.

      EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

      3/26/21 12:15:43 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Neos Therapeutics, Inc.

      EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

      3/26/21 12:15:26 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Neos Therapeutics, Inc.

      EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

      3/26/21 12:15:21 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care

    $NEOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: M John Limongelli disposed to the issuer $0 worth of Common Stock (83,015 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

      3/19/21 6:26:34 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Jr. A. James Robinson disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

      3/19/21 5:36:41 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: W. Gerald Mclaughlin disposed to the issuer $0 worth of Common Stock (270,171 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

      3/19/21 5:35:56 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care

    $NEOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

      Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-12) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 10/13/2023. Application Category: NDA, Application Number: 205489, Application Classification: Labeling

      10/16/23 4:40:20 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

      Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-7) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 06/25/2021. Application Category: NDA, Application Number: 205489, Application Classification: Labeling

      6/28/21 5:08:40 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care